Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: Colon Cancer

In brief

This is an exploratory phase 2, randomized placebo-controlled trial with stratification for disease and chemotherapy type. The study is subsequently closed to enrollment in all arms except patients with metastatic colorectal cancer which would be randomized to either capecitabine plus perifosine or capecitabine alone. The effects of perifosine may be manifested by increased time to progression, tumor regression reflected in partial or complete responses, or a combination of these outcomes. The primary goal of this trial is to obtain a preliminary and objective assessment of the effects of perifosine on time to progression.

Key facts

Study ID

NCT00398879

Run by

AEterna Zentaris

People needed

381

Starts

2005-08-01

Expected to finish

2011-10-01

Last updated by the study team

2018-03-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• In the opinion of the treating physician, treatment with one of the following regimens should represent an appropriate treatment for the patient.
• Capecitabine 825 mg/m2 BID days 1 - 14 q 3 weeks
• Patients should have a histologically or cytologically confirmed diagnosis of colorectal cancer.
• Patients must have received at least one but no more than two prior chemotherapy regimen(s) for the treatment of metastatic or recurrent disease.
• ECOG performance status 0 or 1.
• Leukocytes >= 4,000/μL
• absolute neutrophil count >= 1,500/ μL
• platelets >= 100,000/ μL
• HCT > 28% (with or without growth factor support)
• Creatinine <= 2.5 mg/dl
• total bilirubin < 1.5 x upper limit of normal
• transaminase < 2.5 x upper limit of normal
• Patients must have recovered from acute toxicity-excluding alopecia-related to prior therapy, including surgery or radiotherapy.
• Patients with brain metastases may be admitted, provided the disease has been treated and been stable for 2 months.
• Patients must have ability to understand and the willingness to sign a written informed consent document.

You may not qualify if…

• Patients receiving any other investigational agents or devices.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, psychiatric illness, or social situations that would limit compliance with study requirements.
• HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study due to potential pharmacokinetic interactions with perifosine.
• Patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within 6 months of enrollment), or New York Heart Assoc. class II - IV congestive heart failure.
• Female patients who are pregnant or lactating are ineligible.

Where it is running

• AOI Pharmaceuticals Investigative Site — Tucson, Arizona, United States
• AOI Pharmaceuticals Investigative Site — Beverly Hills, California, United States
• AOI Pharmaceuticals Investigative Site — Deer Park, California, United States
• AOI Pharmaceuticals Investigative Site — Monterey, California, United States
• AOI Pharmaceuticals Investigative Site — Newport Beach, California, United States
• AOI Pharmaceuticals Investigative Site — Pomona, California, United States
• AOI Pharmaceuticals Investigative Site — Santa Rosa, California, United States
• AOI Pharmaceuticals Investigative Site — Soquel, California, United States
• AOI Pharmaceuticals Investigative Site — Stockton, California, United States
• AOI Pharmaceuticals Investigative Site — Colorado Springs, Colorado, United States
• AOI Pharmaceuticals Investigative Site — Greeley, Colorado, United States
• AOI Pharmaceuticals Investigative Site — Middletown, Connecticut, United States
• AOI Pharmaceuticals Investigative Site — Norwich, Connecticut, United States
• AOI Pharmaceuticals Investigative Site — Aventura, Florida, United States
• AOI Pharmaceuticals Investigative Site — Coral Springs, Florida, United States
• AOI Pharmaceuticals Investigative Site — Lake City, Florida, United States
• AOI Pharmaceuticals Investigative Site — Miami, Florida, United States
• AOI Pharmaceuticals Investigative Site — Ormond Beach, Florida, United States
• AOI Pharmaceuticals Investigative Site — Sebastian, Florida, United States
• AOI Pharmaceuticals Investigative Site — Vero Beach, Florida, United States
• AOI Pharmaceuticals Investigative Site — Augusta, Georgia, United States
• AOI Pharmaceuticals Investigative Site — Lawrenceville, Georgia, United States
• AOI Pharmaceuticals Investigative Site — Marietta, Georgia, United States
• AOI Pharmaceuticals Investigative Site — Galesburg, Illinois, United States
• AOI Pharmaceuticals Investigative Site — Park Ridge, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.